{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T16:01:25Z","timestamp":1777910485487,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Journal Armed Forces India"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.mjafi.2021.07.009","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T23:57:22Z","timestamp":1634083042000},"page":"S6-S12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S1","title":["Use of secukinumab in erythrodermic psoriasis: A single center experience"],"prefix":"10.1016","volume":"79","author":[{"given":"Anuj","family":"Bhatnagar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev Kumar","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barnali","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debdeep","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chetan","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunmeet","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.mjafi.2021.07.009_bib1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaad.2009.05.048","article-title":"Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation","volume":"62","author":"Rosenbach","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.mjafi.2021.07.009_bib2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/01.ASW.0000463573.40637.73","article-title":"A review of the diagnosis and management of erythroderma (generalized red skin)","volume":"28","author":"Mistry","year":"2015","journal-title":"Adv Skin Wound Care"},{"issue":"4","key":"10.1016\/j.mjafi.2021.07.009_bib3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11596-017-1773-1","article-title":"Clinical analysis of 84 cases of erythrodermic psoriasis and 121 cases of other types of erythroderma from 2010-2015","volume":"37","author":"Zhang","year":"2017","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"10.1016\/j.mjafi.2021.07.009_bib4","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1001\/jama.1932.02740770032007","article-title":"Erythroderma psoriaticum","volume":"99","author":"Goeckerman","year":"1932","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.mjafi.2021.07.009_bib5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/jid.1956.58","article-title":"Action of synthetic antimalarial drugs on psoriasis","volume":"26","author":"Cornbleet","year":"1956","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.mjafi.2021.07.009_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ard.23.1.12","article-title":"The link between Reiter's syndrome and psoriatic arthritis","volume":"23","author":"Wright","year":"1964","journal-title":"Ann Rheum Dis"},{"issue":"suppl 1","key":"10.1016\/j.mjafi.2021.07.009_bib7","first-page":"1","article-title":"Secukinumab: the anti-IL-17A biologic for the treatment of psoriasis","volume":"11","author":"Fargnoli","year":"2019","journal-title":"Case Rep Dermatol. Sep"},{"issue":"1","key":"10.1016\/j.mjafi.2021.07.009_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/jid.2008.194","article-title":"Psoriasis is characterized by accumulation of immunostimulatory and Th1\/Th17 cell-polarizing myeloid dendritic cells","volume":"129","author":"Zaba","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/j.mjafi.2021.07.009_bib9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.it.2011.06.007","article-title":"T helper 17 cell heterogeneity and pathogenicity in autoimmune disease","volume":"32","author":"Ghoreschi","year":"2011","journal-title":"Trends Immunol"},{"issue":"5","key":"10.1016\/j.mjafi.2021.07.009_bib10","first-page":"1092","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br J Dermatol"},{"issue":"suppl 1","key":"10.1016\/j.mjafi.2021.07.009_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0001-7310(14)70014-6","article-title":"Pathogenic role of IL-17 in psoriasis and psoriatic arthritis","volume":"105","author":"Chiricozzi","year":"2014","journal-title":"Actas Dermosifiliogr"},{"issue":"9","key":"10.1016\/j.mjafi.2021.07.009_bib12","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2217\/imt.15.50","article-title":"Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis","volume":"7","author":"Chen","year":"2015","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.mjafi.2021.07.009_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2040622317738910","article-title":"Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis","volume":"9","author":"Frieder","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"issue":"6","key":"10.1016\/j.mjafi.2021.07.009_bib14","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2147\/TCRM.S3094","article-title":"Treatment of severe psoriasis with infliximab","volume":"4","author":"Leman","year":"2008","journal-title":"Therapeut Clin Risk Manag"},{"issue":"6","key":"10.1016\/j.mjafi.2021.07.009_bib15","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3390\/jcm8060770","article-title":"Use of secukinumab in a cohort of erythrodermic psoriatic patients: a pilot study","volume":"8","author":"Damiani","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.mjafi.2021.07.009_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.14234","article-title":"Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis","author":"Mugheddu","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.mjafi.2021.07.009_bib17","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/1744666X.2016.1246957","article-title":"Brodalumab for the treatment of psoriasis","volume":"12","author":"Galluzzo","year":"2016","journal-title":"Expet Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.mjafi.2021.07.009_bib18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/1346-8138.13622","article-title":"Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J)","volume":"44","author":"Saeki","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.mjafi.2021.07.009_bib19","first-page":"1","article-title":"A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab","author":"Galluzzo","year":"2018","journal-title":"J Dermatol Treat"},{"issue":"2","key":"10.1016\/j.mjafi.2021.07.009_bib20","first-page":"91","article-title":"Erythrodermic psoriasis: current and future role of biologicals","volume":"29","author":"Stinco","year":"2015","journal-title":"Biopharmaceuticals and gene therapy"},{"key":"10.1016\/j.mjafi.2021.07.009_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12611","article-title":"Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis","author":"Dogra","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.mjafi.2021.07.009_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12607","article-title":"Erythrodermic psoriasis and secukinumab: our clinical experience","author":"Mateu-Puchades","year":"2018","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.mjafi.2021.07.009_bib23","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/bjd.16252","article-title":"Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series","volume":"178","author":"Weng","year":"2018","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.mjafi.2021.07.009_bib24","doi-asserted-by":"crossref","first-page":"e420","DOI":"10.1111\/jdv.14234","article-title":"Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis","volume":"31","author":"Mugheddu","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.mjafi.2021.07.009_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/1346-8138.15655","article-title":"Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: real-world evidence in Japan","volume":"48","author":"Fujita","year":"2021","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.mjafi.2021.07.009_bib26","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s11845-020-02336-x","article-title":"Practical experience of secukinumab in the treatment of psoriasis: experience from a single centre","volume":"190","author":"Griffin","year":"2021","journal-title":"Ir J Med Sci"},{"issue":"1","key":"10.1016\/j.mjafi.2021.07.009_bib27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jdv.16558","article-title":"Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)","volume":"35","author":"Bagel","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Medical Journal Armed Forces India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0377123721002197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0377123721002197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:54:23Z","timestamp":1759838063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0377123721002197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":27,"alternative-id":["S0377123721002197"],"URL":"https:\/\/doi.org\/10.1016\/j.mjafi.2021.07.009","relation":{},"ISSN":["0377-1237"],"issn-type":[{"value":"0377-1237","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of secukinumab in erythrodermic psoriasis: A single center experience","name":"articletitle","label":"Article Title"},{"value":"Medical Journal Armed Forces India","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mjafi.2021.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}